Sorafenib: delivering a targeted drug to the right targets (Q36817095)

16 August 2017

1 reference

title

Sorafenib: delivering a targeted drug to the right targets (English)

1 reference

16 August 2017

1

Keith T Flaherty

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

617-626

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Tumor regression by targeted gene delivery to the neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Tumor-host immune interactions and dendritic cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

Phase II study of paclitaxel and carboplatin for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.617

21 January 2018

Identifiers

DOI

10.1586/14737140.7.5.617

1 reference

16 August 2017

1 reference